FDA
-
-
-
-
-
-
-
FDA approves Viridian's Lumvoa for thyroid eye disease
-
-
-
-
-
-
-
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
-
-
-
-
-
-
-
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
-
-
-
-
-
-
-
Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001
-
-
-
-
-
-
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
-
328,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

